1. Australia Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Medical Developments International Limited

Medical Developments International Limited

MDDVF
Medical Developments International LimitedUS flagOther OTC
0.37
USD
- -
- -
41.68MMarket Cap
Medical Developments International Limited
MDDVF
(Other OTC)

Recent

price

0.37

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.15
0.19
0.2
0.2
0.16
0.19
0.24
0.27
0.28
0.31
0.33
0.35
0.3
0.37
0.37
0.36
Revenue per Share
0.02
0.03
0.05
0.04
0.01
0.03
0.03
0.03
- -
0.02
0.01
-0.18
-0.17
-0.06
-0.46
- -
Basic EPS, GAAP
-0.01
-0.02
-0.04
-0.05
-0.03
-0.03
-0.07
-0.14
-0.17
-0.15
-0.13
-0.09
-0.07
-0.09
-0.04
-0.01
Free Cash Flow per Basic Share
- -
- -
0.02
0.04
0.01
- -
0.01
0.02
0.02
0.03
0.03
- -
- -
- -
- -
- -
Dividend per Share
0.23
0.27
0.29
0.27
0.26
0.29
0.31
0.35
0.33
0.64
0.6
0.91
0.71
0.87
0.48
0.47
Book Value per Share
0.07
0.09
0.08
0.02
- -
0.02
-0.03
-0.04
-0.17
0.09
-0.02
0.41
0.22
0.5
0.26
0.3
Tangible Book Value per Share
54
54
56
59
60
60
60
61
62
67
68
71
74
87
89
110
Basic Weighted Avg Shares
8
10
11
12
9
12
14
16
17
21
23
25
22
32
33
39
Sales/Revenue/Turnover
10.4
18.45
28.19
24.4
4.61
15.2
0.76
-4.72
-7.69
-5.23
-11.08
-38.47
-68.26
-63.55
-50.88
-4.51
Operating Margin (%)
- -
- -
- -
- -
- -
- -
1
1
2
2
3
4
3
3
3
3
Depreciation Expense
1
2
3
2
1
2
2
2
- -
1
- -
-13
-12
-6
-41
- -
Net Income, GAAP
30.95
30.14
28.64
27.66
- -
29.73
31.81
26.11
19.27
33.08
- -
- -
- -
- -
- -
44.05
Effective Tax Rate (%)
10.6
17.08
23.9
19.68
9.34
13.17
10.92
11.07
1.39
4.97
1.68
-49.72
-55.47
-17.44
-123.66
0.24
Profit Margin (%)
3
4
5
2
1
3
7
5
3
27
18
40
24
27
17
28
Working Capital
- -
- -
- -
- -
1
1
- -
- -
9
- -
3
3
2
2
2
2
LT Debt
13
14
16
16
16
17
19
22
21
45
43
68
57
81
46
55
Total Equity
4.78
9.48
14.5
12.29
- -
6.47
0.35
-2.51
-4.14
-1.9
- -
- -
- -
- -
- -
-1.87
Return on Invested Capital (%)
7.29
13.03
17.84
13.88
- -
8.26
8.35
8.9
1.39
2.98
- -
- -
- -
- -
- -
0.27
Return on Capital (%)
7.28
13.03
17.84
14.51
5.54
9.2
8.68
9.08
1.17
3.27
0.9
-23.68
-21.17
-8.76
-69.22
0.2
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.95%
12.03%
20.49%
Free Cash Flow
16.35%
-25.13%
-67.18%
Net Income, GAAP
-274.51%
-588.15%
-100.23%
Sales/Revenue/Turnover
13.73%
13.07%
17.82%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
32
2024
- -
- -
- -
- -
33
2025
- -
- -
- -
- -
39

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.06
2024
- -
- -
- -
- -
-0.46
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
StateHouse Holdings Inc. (STHZF)
Charlotte's Web Holdings, Inc. (CWEB.TO)
Allied Biotech Corporation (1780.TWO)
Lupin Limited (LUPIN.BO)
CanaFarma Hemp Products Corp. (CNFA.CN)
Caplin Point Laboratories Ltd. (CAPLIPOINT.BO)
Business
Medical Developments International Limited Medical Developments International Limited is an Australia-based specialised healthcare company that develops, manufactures and distributes innovative emergency medical solutions focused on acute pain management and respiratory care. Founded in 1971 and headquartered in Scoresby, Victoria, the company offers Penthrox (methoxyflurane), a fast-acting inhaled analgesic for trauma, procedural and emergency pain relief delivered via its patented green whistle device; an advanced range of Breath-A-Tech spacers and respiratory medication delivery devices compatible with pressurised metered dose inhalers for asthma and chronic obstructive pulmonary disease (COPD) management in hospital and home settings; oxygen delivery systems; carbon dioxide absorbers; portable nebulisers; peak flow meters; and veterinary anaesthetic machines and equipment. Its products are registered in over 40 countries across Australia, Asia, Europe, the United States and other regions, serving healthcare professionals, hospitals, ambulance services, sports medicine providers and veterinary markets with a focus on improving patient outcomes through industry-leading innovation. In recent developments, the company completed distribution transitions in France and Switzerland, including a new partnership agreement with Labatec Pharma SA in 2025 to accelerate commercialisation of pain management products in Switzerland; achieved 43% growth in Australian hospital volumes for Penthrox and 15% underlying demand increase in Europe during fiscal year 2025; gained paediatric indication approval in Ireland with further European approvals pending; reported group revenue of $39.1 million for fiscal 2025, up 18% year-over-year with improved margins and cash flow; and continues US expansion in the respiratory spacer segment while embedding Penthrox as a standard of care through enhanced partner engagement, real-world evidence and health-economic analyses.